Sunshine Biopharma, Inc. (SBFM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sunshine Biopharma, Inc. (SBFM) trades at $1.16 with AI Score 22/100 (Grade F). Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company focused on developing anticancer and anti-coronavirus drugs. Market cap: $2.76M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SBFM: SBFM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SBFM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SBFM: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sunshine Biopharma, Inc. (SBFM) Healthcare & Pipeline Overview
Sunshine Biopharma, Inc. develops anticancer drugs and nutritional supplements, with a focus on Adva-27a for treating various cancers and SBFM-PL4 as a potential anti-coronavirus treatment. The company operates within the specialty and generic drug manufacturing sector, facing competition from established pharmaceutical companies.
What Is the Investment Thesis for SBFM?
Sunshine Biopharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's success hinges on the clinical development and regulatory approval of its drug candidates, Adva-27a and SBFM-PL4. While Adva-27a targets a broad range of cancers, its ultimate market potential depends on demonstrating superior efficacy and safety compared to existing treatments. Similarly, SBFM-PL4's success in the anti-coronavirus market is contingent on its ability to compete with established vaccines and therapies. With a market capitalization of $2.76M and a negative P/E ratio of -0.86, the company's valuation reflects the speculative nature of its pipeline. Key catalysts include the progression of Adva-27a through clinical trials and the potential for partnerships or licensing agreements. However, investors should be aware of the significant risks associated with drug development, including clinical trial failures, regulatory hurdles, and the need for additional capital.
Based on FMP financials and quantitative analysis
SBFM Key Highlights
Market Cap of $2.76M reflects the early-stage nature and speculative valuation of the company.
- Gross Margin of 33.0% indicates potential profitability in the nutritional supplement segment, but this is offset by R&D expenses.
- Negative P/E ratio of -0.86 highlights the company's current lack of profitability due to ongoing research and development costs.
- Beta of 1.64 suggests the stock is more volatile than the market, reflecting the high-risk nature of biotechnology investments.
- No dividend is paid, which is typical for growth-oriented biotech companies focused on reinvesting earnings into R&D.
Who Are SBFM's Competitors?
SBFM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $1.45 | +0.69% | $6.23M | 30 |
| BFRI Biofrontera Inc. | $1.48 | +4.23% | $19.0M | — |
| EVOK Evoke Pharma, Inc. | $11.00 | +0.00% | $19.0M | 56 |
| HCWB HCW Biologics Inc. | $2.12 | -7.83% | — | |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SBFM's Key Strengths?
Proprietary anticancer drug candidate (Adva-27a).
- Potential anti-coronavirus treatment (SBFM-PL4).
- Established nutritional supplement line.
- License agreement with the University of Georgia.
What Are SBFM's Weaknesses?
Limited financial resources.
- Early-stage drug development pipeline.
- Dependence on regulatory approvals.
- Small market capitalization.
What Could Drive SBFM Stock Higher?
Clinical trial results for Adva-27a in various cancer indications.
- Regulatory submissions for Adva-27a and SBFM-PL4.
- Potential partnerships and licensing agreements with larger pharmaceutical companies.
- Expansion of the nutritional supplement line with new products.
- Progress in preclinical studies for SBFM-PL4.
What Are the Key Risks for SBFM?
Financial-distress signal — its Altman Z-Score of -1.57 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-24.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Adva-27a or SBFM-PL4.
- Regulatory delays or rejections for drug candidates.
- Competition from established pharmaceutical companies.
- Need for additional capital to fund research and development.
- Dependence on key personnel.
What Are the Growth Opportunities for SBFM?
- Adva-27a Clinical Development: The advancement of Adva-27a through clinical trials represents a significant growth opportunity for Sunshine Biopharma. Positive clinical trial results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The market for cancer therapies is estimated to reach $200 billion by 2026, offering a large addressable market for Adva-27a. The timeline for this growth opportunity depends on the successful completion of clinical trials, which typically take several years.
- SBFM-PL4 Anti-Coronavirus Treatment: The development of SBFM-PL4 as an anti-coronavirus treatment offers another growth avenue for the company. While the vaccine market is saturated, there remains a need for effective treatments for those infected with the virus. The global market for COVID-19 therapeutics is projected to reach $25 billion by 2027. The timeline for this growth opportunity depends on preclinical and clinical trial results, as well as regulatory approvals.
- Nutritional Supplement Expansion: Sunshine Biopharma can expand its nutritional supplement business by introducing new products and increasing its distribution channels. The global nutritional supplement market is expected to reach $278 billion by 2028. The company can leverage its scientific expertise to develop innovative supplements that cater to specific health needs. The timeline for this growth opportunity is relatively short, as new products can be launched within a year.
- Partnerships and Licensing Agreements: Forming strategic partnerships and licensing agreements with larger pharmaceutical companies can accelerate the development and commercialization of Sunshine Biopharma's drug candidates. These partnerships can provide access to funding, expertise, and distribution networks. The timeline for this growth opportunity is uncertain, as it depends on finding suitable partners and negotiating favorable terms.
- Geographic Expansion: Expanding into new geographic markets can increase the company's revenue and market share. The company can target countries with growing healthcare spending and unmet medical needs. The timeline for this growth opportunity depends on regulatory approvals and market entry strategies.
What Are SBFM's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- License agreement with the University of Georgia for anti-coronavirus compound.
- Scientific expertise in drug development and formulation.
- Established brand name in the nutritional supplement market.
What Does SBFM Do?
Sunshine Biopharma, Inc., headquartered in Pointe-Claire, Canada, is a pharmaceutical and nutritional supplement company dedicated to the research and development of innovative anticancer drugs. The company's lead anticancer drug candidate, Adva-27a, is a GEM-difluorinated C-glycoside derivative of podophyllotoxin. Adva-27a is being developed as a treatment for a wide range of cancers, including leukemia, lymphoma, and cancers of the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver. The drug has also shown promise in killing multidrug-resistant cancer cells, such as those found in pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells. In addition to its anticancer program, Sunshine Biopharma is developing SBFM-PL4, an anti-coronavirus treatment compound. The company has a license agreement with the University of Georgia to further the development of SBFM-PL4. Sunshine Biopharma also markets a line of nutritional supplements, including Essential 9, a multivitamin tablet, and Essential Calcium-Vitamin D, a calcium and vitamin D supplement. The company aims to develop and commercialize science-based nutritional supplements to improve health and well-being. Founded with a focus on innovative therapies, Sunshine Biopharma continues to advance its research and development efforts to address unmet medical needs in oncology and infectious diseases.
What Products and Services Does SBFM Offer?
- Researches and develops anticancer drugs.
- Develops anti-coronavirus treatment compounds.
- Offers nutritional supplement tablets.
- Markets calcium and vitamin D supplements.
- Seeks to kill multidrug resistant cancer cells.
- Out-licenses and partners to advance drug candidates.
How Does SBFM Make Money?
- Develops and patents pharmaceutical compounds.
- Conducts preclinical and clinical trials.
- Seeks regulatory approvals for its drug candidates.
- Manufactures and markets nutritional supplements.
- Out-licenses or partners with other companies for drug commercialization.
What Industry Does SBFM Operate In?
Sunshine Biopharma operates in the highly competitive pharmaceutical and biotechnology industry. The industry is characterized by intense research and development efforts, stringent regulatory requirements, and a constant need for innovation. The market for anticancer drugs is substantial and growing, driven by an aging population and increasing cancer incidence rates. The company faces competition from established pharmaceutical giants and smaller biotech firms developing novel cancer therapies. The anti-coronavirus market has also become increasingly crowded, with numerous vaccines and treatments already available. Sunshine Biopharma's success will depend on its ability to differentiate its products and navigate the complex regulatory landscape.
Who Are SBFM's Key Customers?
- Patients suffering from cancer.
- Individuals seeking nutritional supplements.
- Pharmaceutical companies interested in licensing or partnering on drug candidates.
- Healthcare providers who prescribe or recommend the company's products.
Company Profile
Sunshine Biopharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. The company is led by CEO Steve N. Slilaty. SBFM has traded publicly since 2022.
Financial Health
Sunshine Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.57 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Sunshine Biopharma, Inc. stands at -24.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.3%, showing how much profit it generates from its asset base. A current ratio of 5.46 indicates the company holds enough short-term assets to cover its near-term obligations.
SBFM Valuation & Market Position
With a $2.76M market cap, Sunshine Biopharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SBFM's quantitative score of 22/100 is below the peer average of 49/100.
Forward Outlook
Wall Street analysts project Sunshine Biopharma, Inc. revenue of about $35.4M for fiscal 2026, with EPS near $-6.30.
SBFM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the value of their operations.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their drug development pipeline.
- Market perception is buoyed by recent positive news coverage, which has increased interest and engagement among retail investors.
- The company's focus on innovative therapies positions it well in a growing sector, attracting attention from both investors and analysts.
Bear Case
- Concerns about the company's financial sustainability have been raised, with some analysts questioning its ability to fund ongoing research and development.
- Social sentiment has shown volatility, with mixed opinions on the company's long-term viability, reflecting uncertainty among investors.
- Recent regulatory challenges could hinder progress, causing apprehension in the market about timely product approvals.
- Bearish community views emphasize the risks associated with biotech investments, particularly in a competitive landscape where many companies are vying for attention.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SBFM Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Jul 20, 2026
SBFM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SBFM.
Price Targets
Wall Street price target analysis for SBFM.
SBFM MoonshotScore
What does this score mean?
The MoonshotScore rates SBFM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steve N. Slilaty
CEO
Steve N. Slilaty serves as the CEO of Sunshine Biopharma, Inc. His leadership is pivotal in guiding the company's strategic direction, particularly in the research and development of anticancer drugs and nutritional supplements. With experience in the pharmaceutical industry, Slilaty oversees the advancement of the company's drug pipeline, including Adva-27a and SBFM-PL4. His expertise is crucial for navigating the complex regulatory landscape and securing partnerships to drive growth.
Track Record: Under Steve N. Slilaty's leadership, Sunshine Biopharma has focused on developing Adva-27a for various cancers and SBFM-PL4 as an anti-coronavirus treatment. He has overseen the company's research and development efforts, as well as its nutritional supplement business. Slilaty has also been instrumental in securing a license agreement with the University of Georgia to advance the development of SBFM-PL4.
Common Questions About SBFM (Healthcare)
What does the AI Score mean for SBFM?
SBFM holds an AI Score of 22/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company focused on developing anticancer and anti-coronavirus drugs. Their pipeline includes Adva-27a for various cancers …
What does Sunshine Biopharma, Inc. do?
Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development, and commercialization of oncology drugs and nutritional supplements. Their primary focus is on their anticancer drug candidate, Adva-27a, which is being developed to treat various forms of cancer. Additionally, they are developing SBFM-PL4 as a potential anti-coronavirus treatment.
What are the main risks for SBFM?
Sunshine Biopharma faces several key risks inherent in the biotechnology industry. Clinical trial failures for Adva-27a or SBFM-PL4 would significantly impact the company's prospects. Regulatory hurdles, including delays or rejections from the FDA or other regulatory agencies, could also impede the commercialization of its drug candidates. Competition from larger, more established pharmaceutical companies poses a threat to market share.
How does Sunshine Biopharma, Inc. navigate regulatory approval processes?
Sunshine Biopharma, Inc. navigates regulatory approval processes by adhering to strict guidelines set by regulatory bodies such as the FDA. The company meticulously plans and executes preclinical and clinical trials to gather comprehensive data on the safety and efficacy of its drug candidates. They maintain detailed documentation and comply with Good Manufacturing Practices (GMP) to ensure product quality and consistency.
What are the key growth opportunities for SBFM in healthcare?
Sunshine Biopharma, Inc. has several key growth opportunities within the healthcare sector. One significant opportunity lies in expanding the indications for Adva-27a to target a broader range of cancers. Positive clinical trial results in additional cancer types could significantly increase the drug's market potential.
What are the key factors to evaluate for SBFM?
Sunshine Biopharma, Inc. (SBFM) holds an AI score of 22/100 (low). Sunshine Biopharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does SBFM data refresh on this page?
SBFM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SBFM's recent stock price performance?
Sunshine Biopharma, Inc. (SBFM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary anticancer drug candidate (Adva-27a). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SBFM overvalued or undervalued right now?
Sunshine Biopharma, Inc. (SBFM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.